drugset / Trial / NCT03773042

A Study Evaluating Tolerability, Efficacy, and Safety of HSK3486 Injectable Emulsion in Patients

NCT03773042

Phase 2 Completed 64 enrolled Sichuan Haisco Pharmaceutical Group Co., Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

A double-blind, randomized, active controlled, multi-center, parallel group study comparing HSK3486 with Propofol, in patients undergoing a colonoscopy.

Timeline

Start
2016-12
Primary completion
2017-06
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.1 mg/kg
Subject Cipepofol Small molecule 0.2 mg/kg
Subject Cipepofol Small molecule 0.3 mg/kg
Subject Cipepofol Small molecule 0.4 mg/kg
Subject Cipepofol Small molecule 0.5 mg/kg
Comparator Propofol Small molecule 1 mg/kg
Comparator Propofol Small molecule 2 mg/kg

Indications

No indication recorded.